TNM staging system may be superior to Lugano and Ann Arbor systems in predicting the overall survival of patients with primary gastrointestinal lymphoma
- PMID: 26214635
TNM staging system may be superior to Lugano and Ann Arbor systems in predicting the overall survival of patients with primary gastrointestinal lymphoma
Abstract
Purpose: To assess the survival predicting value of TNM, Lugano, and Ann Arbor staging systems in patients with primary gastrointestinal lymphoma (PGL).
Methods: 101 patients with PGL were reviewed. All of them were staged according to TNM, Lugano, or Ann Arbor staging system. Five-year survival overall survival/OS rate was used as major clinical outcome. The prognostic value of different variables like depth of tumor infiltration (T), lymph node status (N), metastasis (M), sex, age, LDH, ECOG performance status (PS), subtypes, and tumor sites were assessed in relation to clinical outcome.
Results: The median follow-up time was 46.6 months (range 1.3-158.6). The estimated 5-year OS rate was 74.22%. In gastric lymphoma ,the 5-year OS rate was well correlated with stage in the TNM system (stage I 100.00%, stage II 87.18%, stage III 75.17%, and stage IV 16.67%. p<0.0001), but there were inverse 5-year OS or overlapped survival in the Lugano (81.48% in stage II, 85.71% in stage IIE) and Ann Arbor systems (69.47% in stage IIE, 66.67% in stage IIIE). In aggressive lymphomas, the 5-year OS of TNM stage I, stage II, stage III , and stage IV was 100.00%, 81.34%, 63.52%, and 16.00%, respectively (p=0.0002), but there were overlapped survival curves in Lugano and Ann Arbor systems. The 5-year OS of patients with T1 or T2 was significantly superior compared to patients with T3 or T4 (96.15 vs 67.92%, p=0.0087), and multivariate Cox analysis showed that T (p=0.0181) and M (p=0.0031) were the covariates prognostically significant for OS.
Conclusion: TNM staging system may be superior to Lugano and Ann Arbor system in predicting OS of patients with PGL.
Similar articles
-
Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor.Eur J Ophthalmol. 2013 May-Jun;23(3):344-55. doi: 10.5301/ejo.5000224. Epub 2013 Jan 25. Eur J Ophthalmol. 2013. PMID: 23397158
-
[Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].Zhonghua Yi Xue Za Zhi. 2019 Jun 25;99(24):1853-1858. doi: 10.3760/cma.j.issn.0376-2491.2019.24.004. Zhonghua Yi Xue Za Zhi. 2019. PMID: 31269579 Chinese.
-
Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.JAMA Ophthalmol. 2015 Feb;133(2):165-73. doi: 10.1001/jamaophthalmol.2014.4644. JAMA Ophthalmol. 2015. PMID: 25393033
-
Primary Gastrointestinal Lymphoma: A Retrospective Multicenter Clinical Study of 415 Cases in Chinese Province of Guangdong and a Systematic Review Containing 5075 Chinese Patients.Medicine (Baltimore). 2015 Nov;94(47):e2119. doi: 10.1097/MD.0000000000002119. Medicine (Baltimore). 2015. PMID: 26632732 Free PMC article.
-
Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature.Cancer. 1989 Sep 15;64(6):1208-17. doi: 10.1002/1097-0142(19890915)64:6<1208::aid-cncr2820640608>3.0.co;2-z. Cancer. 1989. PMID: 2670184 Review.
Cited by
-
A Prognostic Model of Gastrointestinal Diffuse Large B Cell Lymphoma.Med Sci Monit. 2021 Aug 27;27:e929898. doi: 10.12659/MSM.929898. Med Sci Monit. 2021. PMID: 34449759 Free PMC article.
-
Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss.J Investig Med High Impact Case Rep. 2016 Dec 1;4(4):2324709616683721. doi: 10.1177/2324709616683721. eCollection 2016 Oct-Dec. J Investig Med High Impact Case Rep. 2016. PMID: 28203570 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical